What few people thought possible little more than a decade ago is now reality: scientifi c and operational advances are greatly reducing the number of deaths from HIV. The number of infant infections has decreased by 58% between 2001 and 2013 and mother-to-child transmission (MTCT) of HIV might well be eliminated in the next few years.
1 By contrast, the prevention and management of hepatitis B virus (HBV) infection lags well behind, at least in sub-Saharan Africa.
The Global Burden of Disease Study 2 highlighted the importance of chronic hepatitis B and its eff ect on health, which is equivalent to that of tuberculosis or malaria. Worldwide about 240 million people have chronic hepatitis B. In sub-Saharan Africa more than 8% of the population are chronic carriers of HBV, 3 the eff ect of which is compounded by the high HIV prevalence. Hepatocellular carcinoma is the second most common cause of cancer in African men and third most common cause of cancer in African women, with more than 75% of cases being related to chronic hepatitis B, despite the availability of a safe and eff ective vaccine for more than two decades.
Early HBV transmission is the main route by which HBV infection is perpetuated in high-prevalence communities. About 90% of children infected through vertical transmission develop chronic hepatitis B. By contrast, 96% of adults will clear primary HBV infection. Therefore, interrupting early transmission is the key to breaking the cycle of ongoing HBV infection.
Active immunisation is the cornerstone of preventing HBV MTCT. By 2012, 181 countries had implemented universal HBV vaccination, with global coverage estimated to be greater than 79%, 3 leading to a remarkable reduction of chronic viral hepatitis B in highburden countries in east Asia. 4 However, sub-Saharan Africa has a low infant HBV vaccine coverage: 72% in 2012. 5 Although the WHO recommends commencing HBV vaccination at birth, 6 in much of Africa the fi rst dose is given at about 6 weeks of age (the monovalent HBV vaccine superseded by the pentavalent vaccine DTP-HepB-Hib in many countries). This vaccination regimen is based on the observation that most African adult patients with chronic hepatitis B are of low infectivity and therefore have a low risk of transmitting perinatally. However, HBV infection in infants who were vaccinated according to this regimen is not uncommon, 7, 9 and studies suggest, although there is a clear regional variation, that up to 38% of pregnant African women with chronic hepatitis B are positive for hepatitis B e antigen (HBeAg) and therefore at high risk of transmitting HBV to their infants. 7, 8 To take full advantage of the benefi ts of the HBV vaccine, its administration should start at birth. The addition of a birth dose to the current three-dose schedule has been shown to be cost-eff ective in low-income countries. 10 Further, where HIV infection is prevalent, an additional dose of HBV vaccine in HIV-exposed babies could well be advantageous, since some data suggest poorer antibody responses in HIV-infected and HIV-exposed uninfected babies. 11 The use of third-generation vaccines with additional viral epitopes (eg, pre-S domain), showing increased antigenicity, is a strategy that deserves investigation.
In resource-rich settings, giving hepatitis B immunoglobulin to infants born to mothers with high HBV viral loads, in addition to birth dose vaccine, is standard of care to prevent HBV MTCT. However, for most women in sub-Saharan countries, the cost and logistics of HBV diagnosis and administration of hepatitis B immunoglobulin are prohibitive.
The administration of antiviral therapy from the second trimester of pregnancy will reduce maternal HBV viral load and decrease the risk of MTCT. 12, 13 The increased access to tenofovir for the treatment of HIV makes administration of this drug a feasible option for prevention of HBV MTCT. Although drugs such as lamivudine and telbivudine have been shown to reduce MTCT, tenofovir has a high barrier to resistance and has been used extensively in HIV-infected pregnant women. It has a good safety profi le in pregnancy, although ongoing vigilance is needed. How can these advances be implemented? Within the constraints of resource-poor settings and in view of their shared approaches, it seems eminently logical to harness the HIV prevention of MTCT infrastructure to address the problem of HBV MTCT. We suggest that identifying women at risk of HBV MTCT with a rapid test, starting and monitoring antiviral therapy in the late second or early third trimester, administering vaccine to the infant at birth, and contact tracing, are all within the expertise of HIV-trained health-care workers. Nevertheless these interventions will require additional resources.
Besides the increase in resources, other hurdles remain. Although tenofovir is available in many countries for HIV therapy, bureaucratic regulations and cost in many areas prevent access for HBV-monoinfected patients. HBV vaccine remains effi cacious when exposed to less stringent cold chains 15 yet package inserts have not been modifi ed to refl ect these data. Additionally, the rollout of pentavalent vaccine might reduce accessibility to monovalent HBV vaccine.
The issue of HBV MTCT deserves our full attention. Screening women for HBV infection and starting antiviral therapy for those who need it, introducing HBV birth dose vaccine, and increasing overall coverage of vaccine are all feasible. What is needed now is strategic political and fi nancial investment that could lead to the elimination of HBV MTCT in sub-Saharan Africa in our lifetime, and in so doing greatly reduce the global burden of this important public health problem.
